EP Patent

EP3876940A1 — Combinations for treating cancer

Assigned to Merck Patent GmbH · Expires 2021-09-15 · 5y expired

What this patent protects

Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased- cytokine agonist, and optionally a PARP inhibitor.

USPTO Abstract

Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased- cytokine agonist, and optionally a PARP inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP3876940A1
Jurisdiction
EP
Classification
—
Expires
2021-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.